| Meta-analysis of Intravitreal Injection of Anti-vascular Endothelial Growth Factors for Diabetic Macular Edema. |
|
Hajin Tchoe, Sang Jin Shin, Jae Kyung Suh, Songhee Cho, Jangmi Yang, Min Joo Kang, Donghyun Jee |
1Office of Economic Evaluation Research, National Evidence Based Healthcare Collaborating Agency, Seoul, Korea.
2Department of Ophthalmology and Visual Science, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. doj087@mail.catholic.ac.kr |
| 당뇨황반부종에서 항혈관성장인자의 유효성과 안전성: 네트워크 메타분석 |
|
최하진1⋅신상진1⋅서재경1⋅조송희1⋅양장미1⋅강민주1⋅지동현2 |
|
한국보건의료연구원 경제성평가연구단1, 가톨릭대학교 의과대학 성빈센트병원 안과 및 시과학교실2 |
Correspondence:
Donghyun Jee,
Email: doj087@mail.catholic.ac.kr
|
|
Received: 3 May 2018 • Revised: 19 June 2018 • Accepted: 24 January 2019 |
| Abstract |
PURPOSE
Intravitreal aflibercept, ranibizumab, bevacizumab, and dexamethasone are the most widely used drugs in the treatment of diabetic macular edema (DME). The aim of this study was to compare the efficacy and safety of anti-vascular endothelial growth factors and dexamethasone for the treatment of DME. METHODS: There were nine previous systematic reviews on this topic; we updated these high-quality reviews. Seven studies were added to two studies following a literature search. Efficacy outcomes were 1) average improvement in visual acuity, 2) proportion of patients who experienced an improvement in vision (an increase in best-corrected visual acuity (BCVA) of ≥ 15 in the Early Treatment Diabetic Retinopathy Study [ETDRS]), and 3) proportion of patients who experienced worsening vision (a decrease in BCVA of ≥ 15 in the ETDRS). Safety outcomes included systemic adverse events and ocular-related adverse events. RESULTS: The mean difference in the BCVA for ranibizumab versus bevacizumab treatment was 0.16 (95% confidence interval [CI]: −0.02, 0.34), and that for ranibizumab versus aflibercept was −0.08 (95% CI: −0.26, 0.10). The mean difference in the change of BCVA for aflibercept versus ranibizumab was −0.20 (95% CI: −0.40, −0.01), and that for aflibercept versus bevacizumab was −0.34 (95% CI: −0.53, −0.14). Other efficacy outcomes showed similar trends, and there was no significant difference between treatments. There was also no significant difference in both systemic and ocular adverse events rates between the treatments. CONCLUSIONS: In DME patients, the efficacy of aflibercept was found to be higher with respect to BCVA changes compared with ranibizumab or bevacizumab. However, there were no significant difference in terms of visual acuity improvement or visual acuity of more than 15 letters, nor in terms of anti-vascular endothelial growth factors (as a safety outcome). |
| Key Words:
Aflibercept;Anti-vascular endothelial growth factor;Diabetic macular edema;Ranibizumab |
|
PDF Links
Full text via DOI
Download Citation
